Kimberly Park serves as Independent Director of the Company. She was Global Vice President of Customer Strategy and Innovation at Merck & Co. from 2014 to 2018 and also held global and U.S. leadership roles at Merck from 1997 to 2005, including U.S. Vice President of Managed Care Marketing. From 2005 to 2014, Ms. Park served in senior leadership roles at Johnson and Johnson, including Founding Partner and Global Vice President of Janssen Healthcare Innovation from 2010 to 2014 and U.S. Vice President of Primary Care Sales and Marketing of Janssen Pharmaceuticals from 2005 to 2010. Prior to joining Merck, Ms. Park held U.S. and global commercial leadership positions at GlaxoSmithKline plc. Ms. Park currently serves on the board of directors of Besser Company, a manufacturer of equipment for the building materials industry, and as a trustee for two private foundations. She is a Mentor for Philadelphia Alliance of Capital and Technology. Ms. Park received her BA in International Business from the University of Michigan.
As the Independent Director of Corcept Therapeutics Inc, the total compensation of Kimberly Park at Corcept Therapeutics Inc is $536,175. There are 10 executives at Corcept Therapeutics Inc getting paid more, with Joseph Belanoff having the highest compensation of $4,958,970.
Kimberly Park is 56, she's been the Independent Director of Corcept Therapeutics Inc since 2019. There are 11 older and 7 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director.
Kimberly's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson a Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: